EUCTR2014-004702-14-DE进行中（未招募）1 期
Efficacy and Tolerability of Menthacarin in Patients (= 18 years old) suffering from symptoms of Irritable Bowel Syndrome (IBS)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adult male or female subject (=18 years old)
- •2. Subject provided a written informed consent in accordance with the legal requirements
- •3. Subject with willingness and ability to comply with all study procedures
- •4. Subjects with a diagnosis of irritable bowel syndrome (IBS) based on the following criteria:
- •5. Presence of IBS symptoms (e.g. abdominal pain, flatulence) for > 3 months
- •6. IBS symptoms are ascribed by both patient and physician to the gut and usually accompanied by altered bowel habits
- •7. The IBS complaints are the reason, why the subject consulted the physician
- •8. No changes characteristic of other diseases are present that are likely to be the cause of the symptoms
- •9. Numeric Rating Scale (NRS) assessing severity of pain > 3 points at visit 1 and visit 2, respectively
- •10. Any reduction in numeric pain rating scale (NRS) assessing severity of pain at visit 2 not greater than one point in comparison to visit 1
- •11. IBS-Severity Scoring System (IBS-SSS) > 80 points at visit 1 and 2, respectively
- •12. Any reduction in IBS-SSS at visit 2 in comparison to visit 1 is < 25 points
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1. History of chronic or evident acute liver, heart, respiratory tract, pulmonary, muscular (e.g. M. gravis) or renal disease
- •2. History or suspected glaucoma (angel-closure glaucoma)
- •3. Subjects with a history of urinary retention by mechanical narrowing of the urinary tract (e.g. enlarged prostate)
- •4. History of renal or hepatic dysfunction (serum creatinine, serum AST or ALT = 3 folds above the upper limit of normal range or alkaline phosphatase > 2 fold above the upper limit of normal) within the last 12 months prior to inclusion into the study
- •5. Subject with known or suspected gall bladder inflammation (cholangitis), is suffering from gall stone, occlusion of the bile ducts or other diseases of the gall bladder, sphincter Oddi dysfunction, or abdominal adhesions
- •6. History or suspected pancreatitis, ileus, or any gastrointestinal bleeding
- •7. Female subject suffering from endometriosis
- •8. Subject is immune-compromised (e.g. AIDS, lymphoma, long-term corticosteroid treatment)
- •9. Subject with malignant tumours or undergoing chemotherapy or radiation therapy
- •10. Evidence of structural abnormality of the gastrointestinal tract or diseases/conditions that affect bowel Transit (e. g. mega-colon)
- •11. Subject is suffering from gastro-oesophageal reflux disease (GERD) or reduced production of gastric acid (achlorhydria)
- •12. Evident or suspected other causes for diarrhoea such microscopic colitis, celiac disease
- •13. Subject is currently experiencing nausea, fever > 38.5 °C (measured using an infrared ear thermometer), vomiting, or bloody diarrhoea
- •14. Subject with history of a gastrointestinal surgery (except appendectomy conducted before one year or longer)
- •15. Subject with clinically significant abnormal results of laboratory tests at the time point of visit 1 (including haematology tests, serum chemistry tests, thyroid function tests)
- •16. Subject is 50 years or older who has been diagnosed with IBS and has not received a colonoscopy in the last 6 months prior to inclusion into the study
- •17. Subject with history of positive test of blood in stool within the last 6 months prior to inclusion into the study
- •18. Subject with history of clinically relevant increase in stool calprotectin within the last 6 months prior to inclusion into the study
- •19. Subject using or has used antipsychotic, antidepressive or anticholinergic medication within one month prior to inclusion into the study
- •20. Previous (within the last 14 days) or concomitant use of analgesics, prokinetics, sedatives, laxatives, anti-diarrhoeal agents, steroidal agents, antacids, proton-pump inhibitors, anti-coagulants, antibiotics or probiotics
- •21. Known or suspected hypersensitivity to the investigational drug or to one of its excipients or to peppermint, menthol, caraway, or to umbelliferous plants or to the rescue medication (BUSCOPAN® PLUS) offered in the study or one of its excipients
- •22. Previous (within the last 30 days) or current use of medications for the treatment of IBS (including herbal preparations)
- •23. Women with positive pregnancy test at visit 1
- •24. Pregnant or breast-feeding women
- •25. Female subject is currently not using an acceptable form of birth control or does not agree to maintain its use throughout the study
- •26. Subject exhibiting or indicating thoughts of suicide currently or in the past
- •27. Subject with no willingness and no ability to comply with all procedures of the trial and is not able to attend all scheduled visits at the
研究者
相似试验
已完成
不适用
A clinical trial to investigate efficacy and safety of Menthacarin® in patients (at least 18 years old) suffering from symptoms of Irritable Bowel Syndrome (IBS)Irritable bowel syndrome (IBS)Digestive SystemISRCTN31630783Dr. Willmar Schwabe GmbH & Co. KG226
进行中（未招募）
1 期
Menthacarin® in the treatment of functional gastrointestinal disordersCTIS2022-501800-92-00Dr. Willmar Schwabe GmbH & Co. KG120
招募中
2 期
Evaluaion of tolerability and efficacy of Melatrance lightening cream for the treatment of melasmaChloasmaIRCT20190210042676N25Knowledge-based company of Janus20
招募中
3 期
Assessment the effect of memantine in the treatment of chemotherapy-induced peripheral neuropathychemotherapy-induced peripheral neuropathy in patients with cancer.Idiopathic peripheral autonomic neuropathyG90.0IRCT20160310026998N12Tabriz University of Medical Sciences180
已完成
2 期
Memantine effect in the treatment of residual symptoms in patients with schizophreniaIRCT2017013032236N2Vice chancellor for research, Mazandaran University of Medical Sciences50